VYNE Therapeutics (NASDAQ:VYNE) Price Target Increased to $9

VYNE Therapeutics (NASDAQ:VYNE – Get Rating) had its price target lifted by Cantor Fitzgerald from $5.00 to $9.00 in a report released on Friday morning, The Fly reports. Separately, HC Wainwright reaffirmed a buy rating and set a $28.00 target price on shares of VYNE Therapeutics in a report on Wednesday, April 19th. VYNE Therapeutics […]

Related Keywords

Patrickg Lepore , , Molecule Stabilizing Technology , Beacon Pointe Advisors , Mackenzie Financial Corp , Cetera Advisor Networks , Therapeutics Inc , Millennium Management , Cantor Fitzgerald , Therapeutics Company Profile , Get Rating , Director Patrick , Financial Corp , Advisor Networks , Pointe Advisors , Molecule Stabilizing , Vyne Therapeutics , Nasdaq Vyne , Vyne , Medical , Boost Price Target ,